2026 Q2 - regnskab
76 dage siden
‧1 t. 2 min
3,75 DKK/aktie
Seneste udbytte
4,51%Direkte afkast
Ordredybde
Antal
Køb
-
Sælg
Antal
-
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| 2 | - | - | ||
| 254 | - | - | ||
| 1.081 | - | - | ||
| 343 | - | - | ||
| 100 | - | - |
Husk på, at en investeret opsparing kan gå både op og ned i værdi. Selvom opsparing i aktier historisk set har givet gode langsigtede afkast, er det ingen garanti for fremtidige afkast. Der er en risiko for, at du ikke får de investerede penge tilbage.
Fonde og ETF'er med aktien
Andre har kigget på
Corporate Actions
Data hentes fra Quartr| Næste begivenhed | |
|---|---|
2026 Q3 - regnskab 4. nov. |
| Tidligere begivenheder | ||
|---|---|---|
2026 Q2 - regnskab 5. aug. | ||
2026 Q1 - regnskab 6. maj | ||
Årlig generalforsamling 2026 26. mar. | ||
2025 Q4 - regnskab 4. feb. | ||
2025 Q3 - regnskab 5. nov. 2025 |
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Debat
Deltag i samtalen med Nordnet Social
17 min. sidenNovo/ CagriSema: Et meget stærkt og klinisk relevant resultat med 25 pct. vægttab for kvinder https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-st%C3%A6rkt-og-klinisk-relevant-resultat-med-25-pct-v%C3%A6gttab-for-kvinder
36 min. sidenLige modtaget fra Novo (15:00) Investigational CagriSema 2.4 mg / 2.4 mg showed significant weight loss among women overall and across pre-, peri- and postmenopausal stages in two post hoc analyses from REDEFINE 1, a phase 3 trial in adults with obesity or overweight¹,² Across the two analyses, CagriSema use was associated with reductions in abdominal fat, as measured by waist circumference, among women overall and across menopause stages¹,² CagriSema is an investigational once-weekly combination of semaglutide, a GLP-1 receptor agonist (RA), and cagrilintide, a long-acting amylin analog Plainsboro, New Jersey, US and Bagsværd, Denmark, 20 October 2026 – Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of 2,309 women with obesity or overweight, CagriSema 2.4 mg / 2.4 mg (cagrilintide 2.4 mg and semaglutide 2.4 mg) was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, if all patients adhered to treatment (efficacy estimand*).1 In a second analysis of 1,902 women with overweight or obesity assigned post hoc by menopausal status, average weight loss at week 68 was 26.7%, 24.8% and 23.1% in premenopausal, perimenopausal and postmenopausal women, compared with 2.1%, 1.7% and 2.6% with placebo, respectively (efficacy estimand*).2 “Many women with obesity or overweight experience weight gain as they move through menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo. “CagriSema has the potential to be the first amylin analog and GLP-1 RA combination therapy for weight management, and these REDEFINE 1 data show it was associated with significant weight loss for women with obesity or overweight. These findings add to the body of evidence from the REDEFINE clinical program.” Women experience major hormonal shifts throughout the different stages of menopause, which can increase abdominal fat accumulation and impact body composition, weight and cardiometabolic risk.2,3 More than 86 million women in the U.S. are aged 40 and older, the years in which perimenopause, menopause and postmenopause occur,4 yet reproductive stage is rarely evaluated as a factor in obesity research.5 In the post hoc analysis of all 2,309 women enrolled in the REDEFINE 1 trial, treatment with CagriSema 2.4 mg / 2.4 mg was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, as well as meaningful improvements in waist circumference – a secondary endpoint of the REDEFINE 1 trial and a measure associated with abdominal fat.1 Change in bodyweight and waist circumference, and achievement of weight-loss targets, among women in REDEFINE 1 at week 68, efficacy estimand results*1 Outcome at week 68 CagriSema 2.4 mg / 2.4 mg (n=1,441) Semaglutide 2.4 mg (n=199) Cagrilintide 2.4 mg (n=208) Placebo (n=461) Baseline bodyweight, mean 101.5 kg 100.2 kg 101.4 kg 102.2 kg Change in bodyweight –25.0% a –19.0% –13.4% –3.0% Change in waist circumference –20.5 cm a –17.4 cm –11.7 cm –4.7 cm Achieved ≥10% bodyweight loss 93.3% a 82.2% 62.0% 12.7% Achieved ≥20% bodyweight loss 68.7% a 38.0% 17.9% 1.8% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-sex interaction testing was not performed In a separate post hoc analysis, 1,902 women with overweight or obesity in REDEFINE 1 who received CagriSema 2.4 mg / 2.4 mg or placebo were evaluated by menopausal stage. Menopause status was derived post hoc using age, medical history, and recorded symptoms and was not based on prospectively collected reproductive staging or biochemical confirmation. CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.2 Change in bodyweight from baseline to week 68, efficacy estimand results*2 Post hoc analysis group by menopause status (CagriSema n / placebo n) CagriSema 2.4 mg / 2.4 mg (change from baseline) Placebo (change from baseline) Premenopausal (408 / 122; baseline 104.3 / 107.1 kg) –26.7% a –2.1% Perimenopausal (256 / 81; baseline 102.7 / 99.6 kg) –24.8% a –1.7% Postmenopausal (530 / 168; baseline 99.1 / 99.3 kg) –23.1% a –2.6% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed “This post hoc analysis from REDEFINE 1 offers new insight into weight loss with investigational CagriSema in women grouped by reproductive life stage,” said Maria D. Hurtado Andrade,
58 min. siden · RedigeretHalllooo marked - Seneste Reuters-nyhed er meget, meget interessant: "To tredjedele af REDEFINE 1 var kvinder, og i denne meget store gruppe ramte CagriSema præcis de 25 %, som markedet oprindeligt havde håbet på." Bum - Til mindst halvdelen af køberne i markedet er CagriSema lige så godt som (og for nogen endnu bedre end) Zepbound.
27 min. sidenTohuuuuuuuuuuuuuuuuuuuuundreogtres Havde jo kaldt den i dag 💰💰💰💰💰💰💰💰 🤑🤑🤑🤑🤑🤑🤑🤑
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Nordnet Social og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Relaterede Produkter
Mæglerstatistik
Største købere
| Mægler | Købt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Nordea Bank Abp | 47.645 | 47.645 | 0 | 47.645 |
| Anonym | 1.679.700 | 1.679.700 | 0 | 0 |
Største sælgere
| Mægler | Købt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Nordea Bank Abp | 47.645 | 47.645 | 0 | 47.645 |
| Anonym | 1.679.700 | 1.679.700 | 0 | 0 |
2026 Q2 - regnskab
76 dage siden
‧1 t. 2 min
3,75 DKK/aktie
Seneste udbytte
4,51%Direkte afkast
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Debat
Deltag i samtalen med Nordnet Social
- 17 min. sidenNovo/ CagriSema: Et meget stærkt og klinisk relevant resultat med 25 pct. vægttab for kvinder https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-st%C3%A6rkt-og-klinisk-relevant-resultat-med-25-pct-v%C3%A6gttab-for-kvinder
- 36 min. sidenLige modtaget fra Novo (15:00) Investigational CagriSema 2.4 mg / 2.4 mg showed significant weight loss among women overall and across pre-, peri- and postmenopausal stages in two post hoc analyses from REDEFINE 1, a phase 3 trial in adults with obesity or overweight¹,² Across the two analyses, CagriSema use was associated with reductions in abdominal fat, as measured by waist circumference, among women overall and across menopause stages¹,² CagriSema is an investigational once-weekly combination of semaglutide, a GLP-1 receptor agonist (RA), and cagrilintide, a long-acting amylin analog Plainsboro, New Jersey, US and Bagsværd, Denmark, 20 October 2026 – Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of 2,309 women with obesity or overweight, CagriSema 2.4 mg / 2.4 mg (cagrilintide 2.4 mg and semaglutide 2.4 mg) was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, if all patients adhered to treatment (efficacy estimand*).1 In a second analysis of 1,902 women with overweight or obesity assigned post hoc by menopausal status, average weight loss at week 68 was 26.7%, 24.8% and 23.1% in premenopausal, perimenopausal and postmenopausal women, compared with 2.1%, 1.7% and 2.6% with placebo, respectively (efficacy estimand*).2 “Many women with obesity or overweight experience weight gain as they move through menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo. “CagriSema has the potential to be the first amylin analog and GLP-1 RA combination therapy for weight management, and these REDEFINE 1 data show it was associated with significant weight loss for women with obesity or overweight. These findings add to the body of evidence from the REDEFINE clinical program.” Women experience major hormonal shifts throughout the different stages of menopause, which can increase abdominal fat accumulation and impact body composition, weight and cardiometabolic risk.2,3 More than 86 million women in the U.S. are aged 40 and older, the years in which perimenopause, menopause and postmenopause occur,4 yet reproductive stage is rarely evaluated as a factor in obesity research.5 In the post hoc analysis of all 2,309 women enrolled in the REDEFINE 1 trial, treatment with CagriSema 2.4 mg / 2.4 mg was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, as well as meaningful improvements in waist circumference – a secondary endpoint of the REDEFINE 1 trial and a measure associated with abdominal fat.1 Change in bodyweight and waist circumference, and achievement of weight-loss targets, among women in REDEFINE 1 at week 68, efficacy estimand results*1 Outcome at week 68 CagriSema 2.4 mg / 2.4 mg (n=1,441) Semaglutide 2.4 mg (n=199) Cagrilintide 2.4 mg (n=208) Placebo (n=461) Baseline bodyweight, mean 101.5 kg 100.2 kg 101.4 kg 102.2 kg Change in bodyweight –25.0% a –19.0% –13.4% –3.0% Change in waist circumference –20.5 cm a –17.4 cm –11.7 cm –4.7 cm Achieved ≥10% bodyweight loss 93.3% a 82.2% 62.0% 12.7% Achieved ≥20% bodyweight loss 68.7% a 38.0% 17.9% 1.8% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-sex interaction testing was not performed In a separate post hoc analysis, 1,902 women with overweight or obesity in REDEFINE 1 who received CagriSema 2.4 mg / 2.4 mg or placebo were evaluated by menopausal stage. Menopause status was derived post hoc using age, medical history, and recorded symptoms and was not based on prospectively collected reproductive staging or biochemical confirmation. CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.2 Change in bodyweight from baseline to week 68, efficacy estimand results*2 Post hoc analysis group by menopause status (CagriSema n / placebo n) CagriSema 2.4 mg / 2.4 mg (change from baseline) Placebo (change from baseline) Premenopausal (408 / 122; baseline 104.3 / 107.1 kg) –26.7% a –2.1% Perimenopausal (256 / 81; baseline 102.7 / 99.6 kg) –24.8% a –1.7% Postmenopausal (530 / 168; baseline 99.1 / 99.3 kg) –23.1% a –2.6% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed “This post hoc analysis from REDEFINE 1 offers new insight into weight loss with investigational CagriSema in women grouped by reproductive life stage,” said Maria D. Hurtado Andrade,
- 58 min. siden · RedigeretHalllooo marked - Seneste Reuters-nyhed er meget, meget interessant: "To tredjedele af REDEFINE 1 var kvinder, og i denne meget store gruppe ramte CagriSema præcis de 25 %, som markedet oprindeligt havde håbet på." Bum - Til mindst halvdelen af køberne i markedet er CagriSema lige så godt som (og for nogen endnu bedre end) Zepbound.27 min. sidenTohuuuuuuuuuuuuuuuuuuuuundreogtres Havde jo kaldt den i dag 💰💰💰💰💰💰💰💰 🤑🤑🤑🤑🤑🤑🤑🤑
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Nordnet Social og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Antal
Køb
-
Sælg
Antal
-
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| 2 | - | - | ||
| 254 | - | - | ||
| 1.081 | - | - | ||
| 343 | - | - | ||
| 100 | - | - |
Husk på, at en investeret opsparing kan gå både op og ned i værdi. Selvom opsparing i aktier historisk set har givet gode langsigtede afkast, er det ingen garanti for fremtidige afkast. Der er en risiko for, at du ikke får de investerede penge tilbage.
Fonde og ETF'er med aktien
Andre har kigget på
Corporate Actions
Data hentes fra Quartr| Næste begivenhed | |
|---|---|
2026 Q3 - regnskab 4. nov. |
| Tidligere begivenheder | ||
|---|---|---|
2026 Q2 - regnskab 5. aug. | ||
2026 Q1 - regnskab 6. maj | ||
Årlig generalforsamling 2026 26. mar. | ||
2025 Q4 - regnskab 4. feb. | ||
2025 Q3 - regnskab 5. nov. 2025 |
Relaterede Produkter
Mæglerstatistik
Største købere
| Mægler | Købt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Nordea Bank Abp | 47.645 | 47.645 | 0 | 47.645 |
| Anonym | 1.679.700 | 1.679.700 | 0 | 0 |
Største sælgere
| Mægler | Købt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Nordea Bank Abp | 47.645 | 47.645 | 0 | 47.645 |
| Anonym | 1.679.700 | 1.679.700 | 0 | 0 |
2026 Q2 - regnskab
76 dage siden
‧1 t. 2 min
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Corporate Actions
Data hentes fra Quartr| Næste begivenhed | |
|---|---|
2026 Q3 - regnskab 4. nov. |
| Tidligere begivenheder | ||
|---|---|---|
2026 Q2 - regnskab 5. aug. | ||
2026 Q1 - regnskab 6. maj | ||
Årlig generalforsamling 2026 26. mar. | ||
2025 Q4 - regnskab 4. feb. | ||
2025 Q3 - regnskab 5. nov. 2025 |
Relaterede Produkter
3,75 DKK/aktie
Seneste udbytte
4,51%Direkte afkast
Debat
Deltag i samtalen med Nordnet Social
- 17 min. sidenNovo/ CagriSema: Et meget stærkt og klinisk relevant resultat med 25 pct. vægttab for kvinder https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-st%C3%A6rkt-og-klinisk-relevant-resultat-med-25-pct-v%C3%A6gttab-for-kvinder
- 36 min. sidenLige modtaget fra Novo (15:00) Investigational CagriSema 2.4 mg / 2.4 mg showed significant weight loss among women overall and across pre-, peri- and postmenopausal stages in two post hoc analyses from REDEFINE 1, a phase 3 trial in adults with obesity or overweight¹,² Across the two analyses, CagriSema use was associated with reductions in abdominal fat, as measured by waist circumference, among women overall and across menopause stages¹,² CagriSema is an investigational once-weekly combination of semaglutide, a GLP-1 receptor agonist (RA), and cagrilintide, a long-acting amylin analog Plainsboro, New Jersey, US and Bagsværd, Denmark, 20 October 2026 – Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of 2,309 women with obesity or overweight, CagriSema 2.4 mg / 2.4 mg (cagrilintide 2.4 mg and semaglutide 2.4 mg) was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, if all patients adhered to treatment (efficacy estimand*).1 In a second analysis of 1,902 women with overweight or obesity assigned post hoc by menopausal status, average weight loss at week 68 was 26.7%, 24.8% and 23.1% in premenopausal, perimenopausal and postmenopausal women, compared with 2.1%, 1.7% and 2.6% with placebo, respectively (efficacy estimand*).2 “Many women with obesity or overweight experience weight gain as they move through menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo. “CagriSema has the potential to be the first amylin analog and GLP-1 RA combination therapy for weight management, and these REDEFINE 1 data show it was associated with significant weight loss for women with obesity or overweight. These findings add to the body of evidence from the REDEFINE clinical program.” Women experience major hormonal shifts throughout the different stages of menopause, which can increase abdominal fat accumulation and impact body composition, weight and cardiometabolic risk.2,3 More than 86 million women in the U.S. are aged 40 and older, the years in which perimenopause, menopause and postmenopause occur,4 yet reproductive stage is rarely evaluated as a factor in obesity research.5 In the post hoc analysis of all 2,309 women enrolled in the REDEFINE 1 trial, treatment with CagriSema 2.4 mg / 2.4 mg was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, as well as meaningful improvements in waist circumference – a secondary endpoint of the REDEFINE 1 trial and a measure associated with abdominal fat.1 Change in bodyweight and waist circumference, and achievement of weight-loss targets, among women in REDEFINE 1 at week 68, efficacy estimand results*1 Outcome at week 68 CagriSema 2.4 mg / 2.4 mg (n=1,441) Semaglutide 2.4 mg (n=199) Cagrilintide 2.4 mg (n=208) Placebo (n=461) Baseline bodyweight, mean 101.5 kg 100.2 kg 101.4 kg 102.2 kg Change in bodyweight –25.0% a –19.0% –13.4% –3.0% Change in waist circumference –20.5 cm a –17.4 cm –11.7 cm –4.7 cm Achieved ≥10% bodyweight loss 93.3% a 82.2% 62.0% 12.7% Achieved ≥20% bodyweight loss 68.7% a 38.0% 17.9% 1.8% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-sex interaction testing was not performed In a separate post hoc analysis, 1,902 women with overweight or obesity in REDEFINE 1 who received CagriSema 2.4 mg / 2.4 mg or placebo were evaluated by menopausal stage. Menopause status was derived post hoc using age, medical history, and recorded symptoms and was not based on prospectively collected reproductive staging or biochemical confirmation. CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.2 Change in bodyweight from baseline to week 68, efficacy estimand results*2 Post hoc analysis group by menopause status (CagriSema n / placebo n) CagriSema 2.4 mg / 2.4 mg (change from baseline) Placebo (change from baseline) Premenopausal (408 / 122; baseline 104.3 / 107.1 kg) –26.7% a –2.1% Perimenopausal (256 / 81; baseline 102.7 / 99.6 kg) –24.8% a –1.7% Postmenopausal (530 / 168; baseline 99.1 / 99.3 kg) –23.1% a –2.6% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed “This post hoc analysis from REDEFINE 1 offers new insight into weight loss with investigational CagriSema in women grouped by reproductive life stage,” said Maria D. Hurtado Andrade,
- 58 min. siden · RedigeretHalllooo marked - Seneste Reuters-nyhed er meget, meget interessant: "To tredjedele af REDEFINE 1 var kvinder, og i denne meget store gruppe ramte CagriSema præcis de 25 %, som markedet oprindeligt havde håbet på." Bum - Til mindst halvdelen af køberne i markedet er CagriSema lige så godt som (og for nogen endnu bedre end) Zepbound.27 min. sidenTohuuuuuuuuuuuuuuuuuuuuundreogtres Havde jo kaldt den i dag 💰💰💰💰💰💰💰💰 🤑🤑🤑🤑🤑🤑🤑🤑
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Nordnet Social og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Antal
Køb
-
Sælg
Antal
-
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| 2 | - | - | ||
| 254 | - | - | ||
| 1.081 | - | - | ||
| 343 | - | - | ||
| 100 | - | - |
Husk på, at en investeret opsparing kan gå både op og ned i værdi. Selvom opsparing i aktier historisk set har givet gode langsigtede afkast, er det ingen garanti for fremtidige afkast. Der er en risiko for, at du ikke får de investerede penge tilbage.
Fonde og ETF'er med aktien
Andre har kigget på
Mæglerstatistik
Største købere
| Mægler | Købt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Nordea Bank Abp | 47.645 | 47.645 | 0 | 47.645 |
| Anonym | 1.679.700 | 1.679.700 | 0 | 0 |
Største sælgere
| Mægler | Købt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Nordea Bank Abp | 47.645 | 47.645 | 0 | 47.645 |
| Anonym | 1.679.700 | 1.679.700 | 0 | 0 |